Yoshiyuki Sankai earned a Ph.D. in Engineering from the University of Tsukuba in Japan in 1987. He has progressed from being a research fellow at the Japan Society for the Promotion of Science (“JSPS”) to assistant professor, associate professor, and then professor at the Graduate School of Systems and Information Engineering, University of Tsukuba. Dr. Sankai is also a visiting professor at Baylor College of Medicine in Houston, Texas in the United States. Currently, he is a professor and Director at the Center for Cybernics Research, University of Tsukuba; the President and CEO of CYBERDYNE, INC.; and a Program Manager of the Impulsing Paradigm Change through Disruptive Technologies (“ImPACT”) program, which was initiated by the Council for Science, Technology and Innovation (“CSTI”) of the Cabinet Office in Japan. He is a fellow of the Robotics Society of Japan (“RSJ”) (2012) and the Society of Instrument and Control Engineers (“SICE”) (2014). He also served as Chairman (2005) and an Executive Board Member (2004-2005) of Advanced Robotics, as well as an Executive Board Member (2000-2012), Congress Head (2003), and President (2003) of the Japan Society of Embolus Detection and Treatment. He was a Council Member on the Global Agenda Councils of the World Economic Forum (2012-2014). He has pioneered innovative cyborg-type robot technology in a new academic field, “Cybernics: the fusion and combination of humans, machines and information systems,” and established a social problem-solving venture company. He led the intellectual property strategy and international standard setting by ISO as an expert member of the committee on the medical robotics field and personal-care robotics field. His robot suit HAL® acquired the medical device CE marking (CE 0197) in August 2013 and its use for medical treatment is being covered by public workers’ compensation insurance in Germany. This feat was followed by an approval from the Ministry of Health, Labour and Welfare in Japan to manufacture and distribute this new medical device in November 2015, and public insurance coverage was approved for medical treatment with HAL® to slow the progression of rare neuromuscular diseases in January 2016. Awards (except for other domestic awards): 2005 World Technology Award (World Technology Network), 2012 Capek Award (INNOROBO), 2014 Technology Pioneer (World Economic Forum), Gold Prize in the 2014 Edison Awards, IPO of the Year in the 2013 DealWatch Awards (Thomson Reuters), and Innovative Equity Deal of the Year in the 2014 DealWatch Awards (Thomson Reuters).